5,6,7,8-四氢-6-(苯甲基)吡啶并[4,3-D]嘧啶-4(4AH)-酮 | 1311254-72-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 5,6,7,8-四氢-6-(苯甲基)吡啶并[4,3-D]嘧啶-4(4AH)-酮
• 英文名称: 6-Benzyl-5,6,7,8-tetrahydropyrido[4,3-D]pyrimidin-4(4AH)-one
• 英文别名: 6-benzyl-4a,5,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-one
• CAS: 1311254-72-4
• 化学式: C₁₄H₁₅N₃O
• mdl: MFCD19382512
• 分子量: 241.29
• InChiKey: UUBYONJHDUREIJ-UHFFFAOYSA-N

物化性质

• 密度：
  1.27

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.357
• 拓扑面积：
  45
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-苄基-3-乙氧羰基-4-哌啶酮盐酸盐 、 醋酸甲脒 以to yield 6-benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(4aH)-one, which的产率得到5,6,7,8-四氢-6-(苯甲基)吡啶并[4,3-D]嘧啶-4(4AH)-酮
  参考文献：
  名称：

  Fused heterocyclic compounds, and compositions and uses thereof

  摘要：

  本文披露了具有1式的融合杂环化合物，其中A、B、L、N、R1、R3、R4'、Y和Z的定义如本文所述。这些化合物及其制剂对哺乳动物，包括人类，的多种疾病的预防和治疗有用，包括但不限于疼痛、炎症、认知障碍、焦虑、抑郁等。

  公开号：

  US20100317676A1

文献信息

• Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and dysfunctions
  申请人：Renovis, Inc.

  公开号：US07745451B2

  公开（公告）日：2010-06-29

  Fused heterocyclic compounds are disclosed that have formula 1: where A, B, L, N, R1, R3, R4′, Y and Z are as defined herein. The compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.

  公开了具有式1的融合杂环化合物：其中A、B、L、N、R1、R3、R4'、Y和Z的定义如本文所述。这些化合物及其制药组合物对于哺乳动物，包括人类的各种疾病的预防和治疗有用，包括但不限于疼痛、炎症、认知障碍、焦虑、抑郁等。
• Tetrahydronaphthyridine and tetrahydropyrido[4,3-D]pyrimidine compounds and compositions thereof useful for the treatment of inflammatory and respiratory diseases
  申请人：Kelly Michael G.

  公开号：US08859545B2

  公开（公告）日：2014-10-14

  Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds are disclosed that have formula 1: where A, B, L, N, R1, R3, R4′, Y and Z are as defined herein. The compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, respiratory conditions, and others.

  本文揭示了具有1式的四氢萘啶和四氢吡咯[4,3-d]嘧啶化合物，其中A、B、L、N、R1、R3、R4'、Y和Z如本文所定义。这些化合物及其制药组合物对哺乳动物包括人类的各种疾病的预防和治疗有用，例如但不限于疼痛、炎症、呼吸道疾病等。
• PYRID-2YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF
  申请人：Wei Zhi-Liang

  公开号：US20110009432A1

  公开（公告）日：2011-01-13

  Fused heterocyclic compounds are provided according to formula 1a or 1b: where R 1 , R 2 , and R 3 are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.

  提供了按照公式1a或1b定义的熔合杂环化合物：其中R1、R2和R3如本文所定义。所提供的化合物及其制剂在哺乳动物中包括人类的预防和治疗各种病症，包括但不限于疼痛、炎症、认知障碍、焦虑、抑郁等。
• FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF
  申请人：Renovis, Inc.

  公开号：EP1885369A2

  公开（公告）日：2008-02-13
• PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF
  申请人：Evotec AG

  公开号：EP2136639B1

  公开（公告）日：2016-03-09